AlphAIalphai — Financial news for AI agents
Zacks CommentaryOCT 314 min read$STVN

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer ...

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 31, 2025, 4:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 1, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
SDZNY vs. STVN: Which Stock Is the Better Value Option? — source image
Source · www.zacks.com
Decision brief

The 30-second read

$STVNNeutralMed
01

Why it matters

Highlights the opportunity in undervalued stocks within the pharma sector, emphasizing valuation metrics and industry trends.

02

Market read

The analysis suggests a moderate positive impact on the pharma sector, especially for undervalued stocks like SDZNY, which could benefit from increased investor attention.

03

What to watch

Potential regulatory hurdles or patent issues could negatively impact SDZNY's valuation; STVN's stability might be undervalued in the current analysis.

Timing: short to medium term (next 3-6 months)

Background

The article compares two pharmaceutical companies, SDZNY and STVN, focusing on their valuation status and investment potential.

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Analyzed as a competitor in the pharmaceutical sector with stable fundamentals.

Expected impact

Likely to remain within a narrow trading range, with potential minor fluctuations.

Evidence & confidence

Strong fundamentals and steady trading volume support stability; however, lack of significant catalysts limits upside.

Market effects

Sector

Potential upward movement in the pharmaceutical sector, especially among undervalued stocks, which could attract investor interest.

Regional

Limited regional impact; primarily relevant to European and global pharma markets.

Global

Moderate; sector-specific news with some influence on global biotech and pharma indices.

Counterpoint

What could challenge this read

SDZNY's valuation may be overly optimistic relative to its growth prospects, risking a correction if industry conditions worsen.

Key entities

  • Company
    Sandoz Group AG

    A global pharmaceutical company specializing in generic and biosimilar medicines.

  • Company
    Stevanato Group

    An Italian manufacturer of drug containment and delivery systems.

Read at source← All news

Related articles

AUG 6
$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

yahoo.com6 min
AUG 5
$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

yahoo.com7 min
AUG 4
$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.

finanznachrichten.de6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min